After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of UroGen Pharma Ltd is $647.35M. A total of 0.58 million shares were traded on the day, compared to an average of 3.01M shares.
In the most recent transaction, Schoenberg Mark sold 5,162 shares of URGN for 7.37 per share on Jun 09 ’25. After the transaction, the Chief Medical Officer now owns 153,378 company shares. In a previous transaction on Jun 09 ’25, Schoenberg Mark bought 5,162 shares at 7.37 per share.
Among the insiders who sold shares, Schoenberg Mark disposed of 4,551 shares on Jan 31 ’25 at a per-share price of $11.14. This resulted in the Chief Medical Officer holding 145,666 shares of URGN after the transaction. In another insider transaction, Smith Jason Drew sold 7,379 shares at $11.14 per share on Jan 31 ’25. Company shares held by the General Counsel now total 26,468.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, URGN has a high of $18.15 and a low of $3.42.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. URGN’s latest balance sheet shows that the firm has $89.14M in Cash & Short Term Investments as of fiscal 2021. There were $398.00k in debt and $22.38M in liabilities at the time. Its Book Value Per Share was -$1.01, while its Total Shareholder’s Equity was $8.41M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for URGN is Buy with a score of 4.75.
